论文部分内容阅读
目的 :观察羟基喜树碱 (HCPT)为主的方案治疗耐药非小细胞肺癌的疗效。方法 :选择耐药晚期肺癌 4 5例 ,随机分为 A、B两组 ,A组 2 2例 ,B组 2 3例 ,A组给予顺铂 (DDP) 6 0 m g/ m2 ,第 1天 ,HCPT10 m g/天 ,第 1～ 5天 ,4周为一个周期 ,连用 3个周期。B组给予 NVB+DDP化疗 ,去甲长春花碱 (NVB) 2 5 m g/ m2 ,第 1、8、15天 ,DDP6 0 mg/ m2 ,第 1天 ,4周为一个周期。结果 :A组 9例、B组 2例在化疗第 1个周期后达 PR,A组和 B组总有效率分别为 4 0 .9%和 8.7% (P <0 .0 5 )。第二周期后 ,A组和 B组总有效率分别为 4 5 .5 %和 13.0 % (P <0 .0 5 )。第三周期后 ,A组 1例达到 CR,但总有效率与第二周期相同。A组中位生存期8个月。B组中位生存期 5个月。毒性反应主要是白细胞和血小板减少。结论 :羟基喜树碱可用于耐药晚期肺癌的治疗 ,毒性反应可以耐受
Objective: To observe the effect of HCPT-based regimen in the treatment of drug resistant non-small cell lung cancer. Methods Forty-five patients with advanced drug-resistant lung cancer were randomly divided into two groups: A group (22 cases) and B group (23 cases). A group received 60 mg / m2 cisplatin (DDP) HCPT 10 mg / day, days 1 to 5, 4 weeks for a cycle, once every 3 cycles. Group B received NVB + DDP chemotherapy, with vinorelbine (NVB) 2.5 mg / m 2, days 1, 8 and 15, and DDP 60 mg / m 2 on day 1 and 4 for one cycle. Results: Nine patients in group A and two patients in group B achieved PR after the first cycle of chemotherapy. The total effective rates in group A and group B were 40.9% and 8.7%, respectively (P <0.05). After the second cycle, the total effective rates in groups A and B were 45.5% and 13.0%, respectively (P <0.05). After the third cycle, one patient in group A achieved CR, but the total effective rate was the same as that in the second cycle. The median survival in group A was 8 months. The median survival in group B was 5 months. Toxicity is mainly white blood cells and thrombocytopenia. CONCLUSION: Hydroxycamptothecin can be used in the treatment of advanced lung cancer with drug resistance and the toxicity can be tolerated